Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toward a better dialogue between neuro-oncologists and phase I investigators.
Massard C, Sandhu S, Blanco M, Papadatos-Pastos D, Carden C, De Bono J, Saran F, Molife LR, Kaye SB, Soria JC, Banerji U. Massard C, et al. Among authors: banerji u. J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4. doi: 10.1200/JCO.2011.39.8347. Epub 2012 Jan 3. J Clin Oncol. 2012. PMID: 22215743 No abstract available.
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P. Banerji U, et al. Cancer Chemother Pharmacol. 2018 Nov;82(5):911-912. doi: 10.1007/s00280-018-3674-9. Cancer Chemother Pharmacol. 2018. PMID: 30173339
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, Workman P, de Bono JS, Gore M, Kaye SB, Banerji U. Carden CP, et al. Among authors: banerji u. Mol Cancer Ther. 2012 Jul;11(7):1609-17. doi: 10.1158/1535-7163.MCT-11-0996. Epub 2012 May 3. Mol Cancer Ther. 2012. PMID: 22556379 Free PMC article.
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, Kristeleit R, Sarker D, Arkenau T, Roxburgh P, Walter HS, Blagden S, Anthoney A, Klencke BJ, Kowalski MM, Banerji U. Jones R, et al. Among authors: banerji u. Clin Cancer Res. 2023 Jan 17;29(2):331-340. doi: 10.1158/1078-0432.CCR-22-2074. Clin Cancer Res. 2023. PMID: 36378548 Free PMC article. Clinical Trial.
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, Rojo F, Routier E, Guarin E, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Soria JC. Martinez-Garcia M, et al. Among authors: banerji u. Clin Cancer Res. 2012 Sep 1;18(17):4806-19. doi: 10.1158/1078-0432.CCR-12-0742. Epub 2012 Jul 3. Clin Cancer Res. 2012. PMID: 22761467 Clinical Trial.
145 results